Adeno-associated virus serotypes: vector toolkit for human gene therapy
Recombinant adeno-associated viral (AAV) vectors have rapidly advanced to the forefront of gene therapy in the past decade. The exponential progress of AAV-based vectors has been made possible by the isolation of several naturally occurring AAV serotypes and over 100 AAV variants from different anim...
Gespeichert in:
Veröffentlicht in: | Molecular therapy 2006-09, Vol.14 (3), p.316-327 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 327 |
---|---|
container_issue | 3 |
container_start_page | 316 |
container_title | Molecular therapy |
container_volume | 14 |
creator | Wu, Zhijian Asokan, Aravind Samulski, R Jude |
description | Recombinant adeno-associated viral (AAV) vectors have rapidly advanced to the forefront of gene therapy in the past decade. The exponential progress of AAV-based vectors has been made possible by the isolation of several naturally occurring AAV serotypes and over 100 AAV variants from different animal species. These isolates are ideally suited to development into human gene therapy vectors due to their diverse tissue tropisms and potential to evade preexisting neutralizing antibodies against the common human AAV serotype 2. Despite their prolific application in several animal models of disease, the mechanisms underlying selective tropisms of AAV serotypes remain largely unknown. Efforts to understand cell surface receptor usage and intracellular trafficking pathways exploited by AAV continue to provide significant insight into the biology of AAV vectors. Such unique traits are thought to arise from differences in surface topology of the capsids of AAV serotypes and variants. In addition to the aforementioned naturally evolved AAV isolates, several strategies to engineer hybrid AAV serotype vectors have been formulated in recent years. The generation of mosaic or chimeric vectors through the transcapsidation or marker-rescue/domain-swapping approach, respectively, is notable in this regard. More recently, combinatorial strategies for engineering AAV vectors using error-prone PCR, DNA shuffling, and other molecular cloning techniques have been established. The latter library-based approaches can serve as powerful tools in the generation of low-immunogenic and cell/tissue type-specific AAV vectors for gene delivery. This review is focused on recent developments in the isolation of novel AAV serotypes and isolates, their production and purification, diverse tissue tropisms, mechanisms of cellular entry/trafficking, and capsid structure. Strategies for engineering hybrid AAV vectors derived from AAV serotypes and potential implications of the rapidly expanding AAV vector toolkit are discussed. |
doi_str_mv | 10.1016/j.ymthe.2006.05.009 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68745994</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68745994</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-68c2264aa2bee78b623a33fc284e3d617c4552a1e9daab6848bae9acc7366383</originalsourceid><addsrcrecordid>eNpdkE9Lw0AUxBdRbK1-AkECgrfE_ZfNxlspWoWCl96XzebFJibZuJsU8u1NbVHw9OYwM2_4IXRLcEQwEY9VNDb9DiKKsYhwHGGcnqE5iWkcYkz5-a8mYoauvK8mReJUXKIZEZJyickcrZc5tDbU3ltT6h7yYF-6wQcenO3HDvxTsAfTWxf01tafZR8Uk94NjW6DD2ghmBY43Y3X6KLQtYeb012g7cvzdvUabt7Xb6vlJjSc0z4U0lAquNY0A0hkJijTjBWGSg4sFyQxPI6pJpDmWmdCcplpSLUxCROCSbZAD8faztmvAXyvmtIbqGvdgh28EjLhcZryyXj_z1jZwbXTNEWSlEo8fT7UsaPLOOu9g0J1rmy0GxXB6gBZVeoHsjpAVjhWE-QpdXfqHrIG8r_MiSr7BoKLebY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1792806238</pqid></control><display><type>article</type><title>Adeno-associated virus serotypes: vector toolkit for human gene therapy</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Wu, Zhijian ; Asokan, Aravind ; Samulski, R Jude</creator><creatorcontrib>Wu, Zhijian ; Asokan, Aravind ; Samulski, R Jude</creatorcontrib><description>Recombinant adeno-associated viral (AAV) vectors have rapidly advanced to the forefront of gene therapy in the past decade. The exponential progress of AAV-based vectors has been made possible by the isolation of several naturally occurring AAV serotypes and over 100 AAV variants from different animal species. These isolates are ideally suited to development into human gene therapy vectors due to their diverse tissue tropisms and potential to evade preexisting neutralizing antibodies against the common human AAV serotype 2. Despite their prolific application in several animal models of disease, the mechanisms underlying selective tropisms of AAV serotypes remain largely unknown. Efforts to understand cell surface receptor usage and intracellular trafficking pathways exploited by AAV continue to provide significant insight into the biology of AAV vectors. Such unique traits are thought to arise from differences in surface topology of the capsids of AAV serotypes and variants. In addition to the aforementioned naturally evolved AAV isolates, several strategies to engineer hybrid AAV serotype vectors have been formulated in recent years. The generation of mosaic or chimeric vectors through the transcapsidation or marker-rescue/domain-swapping approach, respectively, is notable in this regard. More recently, combinatorial strategies for engineering AAV vectors using error-prone PCR, DNA shuffling, and other molecular cloning techniques have been established. The latter library-based approaches can serve as powerful tools in the generation of low-immunogenic and cell/tissue type-specific AAV vectors for gene delivery. This review is focused on recent developments in the isolation of novel AAV serotypes and isolates, their production and purification, diverse tissue tropisms, mechanisms of cellular entry/trafficking, and capsid structure. Strategies for engineering hybrid AAV vectors derived from AAV serotypes and potential implications of the rapidly expanding AAV vector toolkit are discussed.</description><identifier>ISSN: 1525-0016</identifier><identifier>EISSN: 1525-0024</identifier><identifier>DOI: 10.1016/j.ymthe.2006.05.009</identifier><identifier>PMID: 16824801</identifier><language>eng</language><publisher>United States: Elsevier Limited</publisher><subject>Animals ; Dependovirus - classification ; Dependovirus - genetics ; Dependovirus - isolation & purification ; Gene therapy ; Genetic Engineering ; Genetic Therapy ; Genetic Vectors - classification ; Genetic Vectors - isolation & purification ; Genomes ; Humans ; Mice ; Proteins ; Serotyping ; Vectors (Biology) ; Viruses</subject><ispartof>Molecular therapy, 2006-09, Vol.14 (3), p.316-327</ispartof><rights>Copyright Nature Publishing Group Sep 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-68c2264aa2bee78b623a33fc284e3d617c4552a1e9daab6848bae9acc7366383</citedby><cites>FETCH-LOGICAL-c442t-68c2264aa2bee78b623a33fc284e3d617c4552a1e9daab6848bae9acc7366383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16824801$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Zhijian</creatorcontrib><creatorcontrib>Asokan, Aravind</creatorcontrib><creatorcontrib>Samulski, R Jude</creatorcontrib><title>Adeno-associated virus serotypes: vector toolkit for human gene therapy</title><title>Molecular therapy</title><addtitle>Mol Ther</addtitle><description>Recombinant adeno-associated viral (AAV) vectors have rapidly advanced to the forefront of gene therapy in the past decade. The exponential progress of AAV-based vectors has been made possible by the isolation of several naturally occurring AAV serotypes and over 100 AAV variants from different animal species. These isolates are ideally suited to development into human gene therapy vectors due to their diverse tissue tropisms and potential to evade preexisting neutralizing antibodies against the common human AAV serotype 2. Despite their prolific application in several animal models of disease, the mechanisms underlying selective tropisms of AAV serotypes remain largely unknown. Efforts to understand cell surface receptor usage and intracellular trafficking pathways exploited by AAV continue to provide significant insight into the biology of AAV vectors. Such unique traits are thought to arise from differences in surface topology of the capsids of AAV serotypes and variants. In addition to the aforementioned naturally evolved AAV isolates, several strategies to engineer hybrid AAV serotype vectors have been formulated in recent years. The generation of mosaic or chimeric vectors through the transcapsidation or marker-rescue/domain-swapping approach, respectively, is notable in this regard. More recently, combinatorial strategies for engineering AAV vectors using error-prone PCR, DNA shuffling, and other molecular cloning techniques have been established. The latter library-based approaches can serve as powerful tools in the generation of low-immunogenic and cell/tissue type-specific AAV vectors for gene delivery. This review is focused on recent developments in the isolation of novel AAV serotypes and isolates, their production and purification, diverse tissue tropisms, mechanisms of cellular entry/trafficking, and capsid structure. Strategies for engineering hybrid AAV vectors derived from AAV serotypes and potential implications of the rapidly expanding AAV vector toolkit are discussed.</description><subject>Animals</subject><subject>Dependovirus - classification</subject><subject>Dependovirus - genetics</subject><subject>Dependovirus - isolation & purification</subject><subject>Gene therapy</subject><subject>Genetic Engineering</subject><subject>Genetic Therapy</subject><subject>Genetic Vectors - classification</subject><subject>Genetic Vectors - isolation & purification</subject><subject>Genomes</subject><subject>Humans</subject><subject>Mice</subject><subject>Proteins</subject><subject>Serotyping</subject><subject>Vectors (Biology)</subject><subject>Viruses</subject><issn>1525-0016</issn><issn>1525-0024</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpdkE9Lw0AUxBdRbK1-AkECgrfE_ZfNxlspWoWCl96XzebFJibZuJsU8u1NbVHw9OYwM2_4IXRLcEQwEY9VNDb9DiKKsYhwHGGcnqE5iWkcYkz5-a8mYoauvK8mReJUXKIZEZJyickcrZc5tDbU3ltT6h7yYF-6wQcenO3HDvxTsAfTWxf01tafZR8Uk94NjW6DD2ghmBY43Y3X6KLQtYeb012g7cvzdvUabt7Xb6vlJjSc0z4U0lAquNY0A0hkJijTjBWGSg4sFyQxPI6pJpDmWmdCcplpSLUxCROCSbZAD8faztmvAXyvmtIbqGvdgh28EjLhcZryyXj_z1jZwbXTNEWSlEo8fT7UsaPLOOu9g0J1rmy0GxXB6gBZVeoHsjpAVjhWE-QpdXfqHrIG8r_MiSr7BoKLebY</recordid><startdate>200609</startdate><enddate>200609</enddate><creator>Wu, Zhijian</creator><creator>Asokan, Aravind</creator><creator>Samulski, R Jude</creator><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>200609</creationdate><title>Adeno-associated virus serotypes: vector toolkit for human gene therapy</title><author>Wu, Zhijian ; Asokan, Aravind ; Samulski, R Jude</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-68c2264aa2bee78b623a33fc284e3d617c4552a1e9daab6848bae9acc7366383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Animals</topic><topic>Dependovirus - classification</topic><topic>Dependovirus - genetics</topic><topic>Dependovirus - isolation & purification</topic><topic>Gene therapy</topic><topic>Genetic Engineering</topic><topic>Genetic Therapy</topic><topic>Genetic Vectors - classification</topic><topic>Genetic Vectors - isolation & purification</topic><topic>Genomes</topic><topic>Humans</topic><topic>Mice</topic><topic>Proteins</topic><topic>Serotyping</topic><topic>Vectors (Biology)</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Zhijian</creatorcontrib><creatorcontrib>Asokan, Aravind</creatorcontrib><creatorcontrib>Samulski, R Jude</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Zhijian</au><au>Asokan, Aravind</au><au>Samulski, R Jude</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adeno-associated virus serotypes: vector toolkit for human gene therapy</atitle><jtitle>Molecular therapy</jtitle><addtitle>Mol Ther</addtitle><date>2006-09</date><risdate>2006</risdate><volume>14</volume><issue>3</issue><spage>316</spage><epage>327</epage><pages>316-327</pages><issn>1525-0016</issn><eissn>1525-0024</eissn><abstract>Recombinant adeno-associated viral (AAV) vectors have rapidly advanced to the forefront of gene therapy in the past decade. The exponential progress of AAV-based vectors has been made possible by the isolation of several naturally occurring AAV serotypes and over 100 AAV variants from different animal species. These isolates are ideally suited to development into human gene therapy vectors due to their diverse tissue tropisms and potential to evade preexisting neutralizing antibodies against the common human AAV serotype 2. Despite their prolific application in several animal models of disease, the mechanisms underlying selective tropisms of AAV serotypes remain largely unknown. Efforts to understand cell surface receptor usage and intracellular trafficking pathways exploited by AAV continue to provide significant insight into the biology of AAV vectors. Such unique traits are thought to arise from differences in surface topology of the capsids of AAV serotypes and variants. In addition to the aforementioned naturally evolved AAV isolates, several strategies to engineer hybrid AAV serotype vectors have been formulated in recent years. The generation of mosaic or chimeric vectors through the transcapsidation or marker-rescue/domain-swapping approach, respectively, is notable in this regard. More recently, combinatorial strategies for engineering AAV vectors using error-prone PCR, DNA shuffling, and other molecular cloning techniques have been established. The latter library-based approaches can serve as powerful tools in the generation of low-immunogenic and cell/tissue type-specific AAV vectors for gene delivery. This review is focused on recent developments in the isolation of novel AAV serotypes and isolates, their production and purification, diverse tissue tropisms, mechanisms of cellular entry/trafficking, and capsid structure. Strategies for engineering hybrid AAV vectors derived from AAV serotypes and potential implications of the rapidly expanding AAV vector toolkit are discussed.</abstract><cop>United States</cop><pub>Elsevier Limited</pub><pmid>16824801</pmid><doi>10.1016/j.ymthe.2006.05.009</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1525-0016 |
ispartof | Molecular therapy, 2006-09, Vol.14 (3), p.316-327 |
issn | 1525-0016 1525-0024 |
language | eng |
recordid | cdi_proquest_miscellaneous_68745994 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
subjects | Animals Dependovirus - classification Dependovirus - genetics Dependovirus - isolation & purification Gene therapy Genetic Engineering Genetic Therapy Genetic Vectors - classification Genetic Vectors - isolation & purification Genomes Humans Mice Proteins Serotyping Vectors (Biology) Viruses |
title | Adeno-associated virus serotypes: vector toolkit for human gene therapy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T23%3A30%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adeno-associated%20virus%20serotypes:%20vector%20toolkit%20for%20human%20gene%20therapy&rft.jtitle=Molecular%20therapy&rft.au=Wu,%20Zhijian&rft.date=2006-09&rft.volume=14&rft.issue=3&rft.spage=316&rft.epage=327&rft.pages=316-327&rft.issn=1525-0016&rft.eissn=1525-0024&rft_id=info:doi/10.1016/j.ymthe.2006.05.009&rft_dat=%3Cproquest_cross%3E68745994%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1792806238&rft_id=info:pmid/16824801&rfr_iscdi=true |